Antiadhesive effects of GRN163L - An oligonucleotide N3′→ P5′ thio-phosphoramidate targeting telomerase

Cancer Research

Volumn 67, Issue 3, 2007, Pages 1121-1129

  Jackson, Shalmica R ^a   Zhu, Chun Hong ^b   Paulson, Vera ^a   Watkins, Linda ^b,c   Dikmen, Z Gunnur ^a,d   Gryaznov, Sergei M ^e   Wright, Woodring E ^a   Shay, Jerry W ^a,c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d HACETTEPE UNIVERSITY   (Turkey)

^e GERON CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GRN 163L; OLIGONUCLEOTIDE; PHOSPHORAMIDIC ACID DERIVATIVE; TELOMERASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TELOMERE;

AMIDES; ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL ADHESION; CELL LINE, TUMOR; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; OLIGONUCLEOTIDES; OLIGOPEPTIDES; PHOSPHORIC ACIDS; RNA; TELOMERASE; TELOMERE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33847071293     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-2306     Document Type: Article

References (33)

1. Shay JW, Bacchetti S. Survey of telomerase activity in human cancer. Eur J Cancer 1997;33:787-91.
2. Greider C, Blackburn E. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 1985;43:405-13.
3. Lingner J, Cooper J, Cech T. Telomerase and DNA end replication: no longer a lagging strand problem? Science 1995;269:1533-4.
4. Feng J, Funk W, Wang S, et al. The RNA component of human telomerase. Science 1995;269:1236-41.
5. Shay J, Wright W. Senescence and immortalization: role of telomeres and telomerase. Carcinogenesis 2004;26:867-74.
6. Aisner D, Wright W, Shay J. Telomerase regulation: not just flipping the switch. Curr Opin Genet Dev 2002;13:80-5.
7. Forsyth N, Wright W, Shay J. Telomerase and differentiation in multicellular organisms: turn it off, turn it on, and turn it off again. Differentiation 2002;69:188-97.
8. Masutomi K, Yu EY, Khurts S, et al. Telomerase maintains telomere structure in normal human cells. Cell 2003;114:241-53.
9. Gellert G, Jackson S, Dikmen Z, Wright W, Shay J. Telomerase as a therapeutic target in cancer. Drug Discovery Today: Disease Mechanisms 2005;2:159-64.
10. White L, Wright W, Shay J. Telomerase inhibitors. Trends Biotechnol 2001;19:114-20.
11. Resler E, Bearss D, Hurley L. Telomere inhibition and telomere disruption as proceses for drug targeting. Annu Rev Pharmacol Toxicol 2003;43:359-79.
12. Gryaznov S, Pongracz K, Matray T, et al. Telomerase inhibitors- oligonucleotide phosphoramidates as potential therapeutic agents. Nucleosides Nucleotides Nucleic Acids 2001;20:401-10.
13. Herbert B-S, Pongracz K, Shay J, Gryaznov S. Oligonucleotide N3′→P5′ phosphoramidates as efficient telomerase inhibitors. Oncogene 2002;21:638-42.
14. Shay JW, Wright WE. Telomeres in dyskeratosis congentia. Nat Genet 2004;36:437-8.
15. Asai A, Oshima Y, Yamamoto Y, et al. A novel telomerase template antagonist (GRN163) as a potential anticancer agent. Cancer Res 2003;63:3931-9.
16. Ozawa T, Gryaznov S, Hu L, et al. Antitumor effects of specific telomerase inhibitor GHN163 in human glioblastoma xenografts. Neuro-Oncol 2004;6:218-26.
17. Wang ES, Wu K, Chin AC, et al. Telomerase inhibition with an oligonucleotide telomerase template antagonist: in vitro and in vivo studies in multiple myeloma and lymphoma. Blood 2004;103:258-66.
18. Sharma GG, Gupta G, Wang H, et al. hTERT associates with human telomeres and enhances genomic stability and DNA repair. Oncogene 2003;22:131-46.
19. Herbert B-S, Gellert GC, Hochreiter A, et al. Lipid modification of GRN163, a N3′→P5′ thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene 2005;24:5262-8.
20. Djojosubroto M, Chin A, Go N, et al. Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma. Hepatology 2005;42:1127-36.
21. Gellert G, Dikmen Z, Wright W, Gryaznov S, Shay J. Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer. Breast Cancer Res Treat 2006;96:73-81.
22. Dikmen ZG, Gellert GC, Jackson S, et al. In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. Cancer Res 2005;65:7866-73.
23. Perry P, Arnold J, Jenkins T. Telomerase inhibitors for the treatment of cancer: the current perspective. Expert Opin Investig Drugs 2001;10:2141-56.
24. Chen Z, Koeneman KS, Corey DR. Consequences of telomerase inhibition and combination treatments for the proliferation of cancer cells. Cancer Res 2003;63:5917-25.
25. Yi X, Tesmer VM, Savre-Train I, Shay JW, Wright WE. Both transcriptional and posttranscriptional mechanisms regulate human telomerase template RNA levels. Mol Cell Biol 1999;19:3989-97.
26. Akiyama M, Hideshima T, Shammas MA, et al. Effects of oligonucleotide N3′→P5′ thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells. Cancer Res 2003;63:6187-94.
27. Dias N, Stein C. Potential roles of antisense oligonucleotides in cancer therapy. The example of Bcl-2 antisense oligonucleotides. Eur J Pharm Biopharm 2002;54:263-9.
28. Stein C, Cheng Y. Antisense oligonucleotides as therapeutic agents - is the bullet really magical? Science 1993;261:1004-12.
29. Guvakova MA, Yakubov LA, Vlodavsky I, Tonkinson JL, Stein CA. Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J Biol Chem 1995;270:2620-7.
30. Khaled Z, Benimetskaya L, Zeltser R, et al. Multiple mechanisms may contribute to the cellular antiadhesive effects of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res 1996;24:737-45.
31. Sawabata N, Ohta M, Maeda H. Fine-needle aspiration cytologic technique for lung cancer has a high potential of malignant cell spread through the tract. Chest 2000;118:936-9.
32. Buhr J, Hurtgen M, Kelm C, Schwemmle K. Tumor dissemination after thoracoscopic resection for lung cancer. J Thorac Cardiovasc Surg 1995;110:855-6.
33. Downey R, McCormack P. Dissemination of malignant tumors after video-assisted thoracic surgery: a report of twenty-one cases. The video-assisted thoracic surgery study group. J Thorac Cardiovasc Surg 1996;111:954-60.